AxoGen to Present at Lazard Capital Markets Medical Technology Conference
ALACHUA, Fla.-- AxoGen, Inc. (OTCBB: AXGN) a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will be presenting at the Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference.
The event is being held from February 27 - March 1, 2013 at The Cliff Hotel, Snowbird Ski and Summer Resort in Snowbird, Utah. The conference format consists of a full day of one-on-one meetings and will not be webcast.
Institutional investors that wish to request a meeting with AxoGen should contact Lazard Capital Markets or AxoGen Investor Relations.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at www.axogeninc.com.
COCKRELL GROUP
Rich Cockrell, 404-942-3369
Investorrelations@thecockrellgroup.com
cockrellgroup.com
or
AxoGen,
Inc.
Greg Freitag, 386-462-6856
Chief Financial Officer
InvestorRelations@AxoGenInc.com
Source: AxoGen, Inc.
Released February 13, 2013